134,270 Shares in Bruker Corporation $BRKR Bought by Castleark Management LLC

Castleark Management LLC acquired a new stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 134,270 shares of the medical research company's stock, valued at approximately $8,080,000. Castleark Management LLC owned about 0.09% of Bruker as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Royal Bank of Canada raised its position in shares of Bruker by 8.3% during the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company's stock valued at $5,148,000 after buying an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Bruker during the first quarter worth approximately $262,000. Goldman Sachs Group Inc. increased its stake in Bruker by 107.3% during the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company's stock worth $61,162,000 after acquiring an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Bruker by 2.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company's stock valued at $15,285,000 after purchasing an additional 9,235 shares during the period. Finally, Focus Partners Wealth increased its position in shares of Bruker by 115.0% during the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company's stock valued at $469,000 after purchasing an additional 6,008 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. TD Cowen restated a "hold" rating on shares of Bruker in a research report on Wednesday, July 15th. Zacks Research raised shares of Bruker from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 4th. Weiss Ratings raised Bruker from a "sell (d)" rating to a "sell (d+)" rating in a research report on Wednesday, June 3rd. Barclays raised their target price on shares of Bruker from $53.00 to $60.00 and gave the company an "overweight" rating in a research note on Wednesday, June 24th. Finally, Wall Street Zen raised Bruker from a "hold" rating to a "buy" rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Bruker presently has a consensus rating of "Moderate Buy" and an average price target of $56.64.

Bruker Stock Performance

BRKR opened at $56.85 on Wednesday. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $65.30. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The company has a market cap of $8.66 billion, a P/E ratio of -81.21, a price-to-earnings-growth ratio of 1.74 and a beta of 1.28. The firm's 50-day moving average price is $58.69 and its 200-day moving average price is $47.71.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to analysts' expectations of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. Bruker's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the business earned $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts anticipate that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 21st. Bruker's payout ratio is presently -28.57%.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source